US2013101656A1PendingUtilityA1

In situ gelling drug delivery system

53
Assignee: SU DONGLINGPriority: Jun 26, 2003Filed: Sep 12, 2012Published: Apr 25, 2013
Est. expiryJun 26, 2023(expired)· nominal 20-yr term from priority
Inventors:Dongling SuPaul AshtonJianbing Chen
A61P 43/00A61P 25/04A61K 31/382A61K 9/0092A61K 31/196A61K 47/60A61K 47/6903A61K 31/485A61K 47/55A61K 9/06A61K 9/0024A61K 9/0051A61K 47/34A61K 31/542A61K 47/48215
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides liquid controlled-release drug delivery compositions which gel upon injection into the body to form, in situ, controlled-release drug implants. The compositions of the invention feature a gel-forming polymer that is insoluble in water, a polyethylene glycol solvent in which the polymer is dissolved, and the drug substance to be delivered.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A sustained release injectable pharmaceutical composition comprising:
 (a) a prodrug, comprising a drug substance covalently linked to a polyoxyethylene ether; and   (b) a biocompatible and bioerodable poly(DL-lactide-glycolide) (PLGA) polymer;   (c) wherein the prodrug serves as a solvent for the PLGA polymer and the PLGA polymer is dissolved in the prodrug; and   (d) wherein the composition forms a gel phase when said composition comes into contact with water or bodily fluids.   
     
     
         2 . A method for forming a polymeric sustained-release drug delivery gel in a subject, comprising injecting into the subject a composition according to any one of  claim 1 . 
     
     
         3 . A method of administering a composition according to  claim 1  wherein the composition is co-administered with an aqueous fluid. 
     
     
         4 . The method according to  claim 3  wherein the aqueous fluid is buffered saline. 
     
     
         5 . A drug deliver device containing a composition according to  claim 1 . 
     
     
         6 . A device according to  claim 5  wherein the device has at least one opening. 
     
     
         7 . A device according to  claim 5  wherein the device is an open tube. 
     
     
         8 . The composition of  claim 1 , wherein the polyoxyethylene ether is polyethylene glycol (PEG). 
     
     
         9 . The composition of  claim 8 , wherein the average MW of the polyethylene glycol is between about 100 and about 6000. 
     
     
         10 . The composition of  claim 8 , wherein the average MW of the polyethylene glycol is between about 200 and about 400.

Join the waitlist — get patent alerts

Track US2013101656A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.